#BioDlink

Thiard News@F4F

@newsen.bsky.social

2 days ago

BioDlink Earns Title of 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Awards BioDlink has been awarded 'Emerging CDMO of the Year,' recognizing its innovation in biologics and ADC development through advanced technology and quality systems.

BioDlink Earns Title of 'Emerging CDMO of the Year' at Asia-Pacific Biopharma Awards #China #Suzhou #biopharmaceuticals #ADC_Development #BioDlink

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioDlink's Milestone Achievement: Pioneering the First Dual-Payload ADC for Clinical Trials BioDlink has been honored by Chengdu Kanghong Pharmaceutical for its role in the development of the world's first dual-payload ADC, advancing clinical trials ahead of schedule.

BioDlink's Milestone Achievement: Pioneering the First Dual-Payload ADC for Clinical Trials #China #Suzhou #ADC #BioDlink #Kanghong

Thiard News@F4F

@newsen.bsky.social

1 month ago

BioDlink Unveils Veeva QMS Implementation to Elevate Quality Management Standards BioDlink has successfully integrated Veeva QMS into its operations, enhancing quality management and compliance processes, ensuring dynamic evolution in its service delivery.

BioDlink Unveils Veeva QMS Implementation to Elevate Quality Management Standards #China #Suzhou #Quality_Management #BioDlink #Veeva_QMS

Thiard News@F4F

@newsen.bsky.social

3 months ago

BioDlink Unveils Major Advances in Biologics Development Between Europe and China BioDlink showcases its pivotal role in biopharmaceuticals at Biologics CDMO Europe 2025, marking a significant advancement in global collaboration.

BioDlink Unveils Major Advances in Biologics Development Between Europe and China #China #Suzhou #ADCs #Biologics #BioDlink

Thiard News@F4F

@newsen.bsky.social

3 months ago

BioDlink and Lepu Biopharma Join Forces to Release the First EGFR-Targeting ADC Drug BioDlink and Lepu Biopharma mark a significant milestone with the launch of MEIYOUHENG®, the first EGFR-targeting ADC drug, showcasing their collaborative achievement in biologics.

BioDlink and Lepu Biopharma Join Forces to Release the First EGFR-Targeting ADC Drug #China #Suzhou #BioDlink #Lepu_Biopharma #MEIYOUHENG

Thiard News@F4F

@newsen.bsky.social

4 months ago

BioDlink Celebrates Major Milestone with Lepu Biopharma's EGFR-Targeted ADC Approval BioDlink congratulates Lepu Biopharma for the historic approval of the world's first EGFR-targeted ADC, revolutionizing treatment for cancer patients.

BioDlink Celebrates Major Milestone with Lepu Biopharma's EGFR-Targeted ADC Approval #China #Suzhou #BioDlink #Lepu_Biopharma #EGFR-Targeted

Thiard News@F4F

@newsen.bsky.social

4 months ago

BioDlink Successfully Ships Bevacizumab to Colombia, Paving Way for Cancer Treatment Access BioDlink's first international shipment of Bevacizumab injection to Colombia marks a significant advancement in targeted cancer therapy.

BioDlink Successfully Ships Bevacizumab to Colombia, Paving Way for Cancer Treatment Access #Colombia #Kexing_Biopharm #BioDlink #Bevacizumab

Thiard News@F4F

@newsen.bsky.social

6 months ago

BioDlink Secures Authorization for Bevacizumab Launch in Indonesia, Continuing Global Expansion BioDlink's Bevacizumab Injection has been approved in Indonesia, marking a significant step in their global expansion and enhancing patient access to vital treatments.

BioDlink Secures Authorization for Bevacizumab Launch in Indonesia, Continuing Global Expansion #Indonesia #Jakarta #BioDlink #Bevacizumab

Thiard News@F4F

@newsen.bsky.social

7 months ago

BioDlink's Bevacizumab Launch in Colombia and Pakistan Marks New Era in Oncology Treatments BioDlink accelerates its global growth with successful bevacizumab launches in Colombia and Pakistan, striving to enhance oncology treatment access.

BioDlink's Bevacizumab Launch in Colombia and Pakistan Marks New Era in Oncology Treatments #China #Suzhou #Kexing_Biopharm #BioDlink #Bevacizumab

Thiard News@F4F

@newsen.bsky.social

8 months ago

BioDlink's Global Biologics Innovation: A Catalyst for Biotech Advancement Discover how BioDlink is spearheading global biopharmaceutical advancement through collaboration and innovation in the biotech ecosystem.

BioDlink's Global Biologics Innovation: A Catalyst for Biotech Advancement #China #Suzhou #biopharmaceuticals #Biotech_Innovation #BioDlink

Thiard News@F4F

@newsen.bsky.social

8 months ago

BioDlink's Bevacizumab Gains Nigeria Approval, Enhancing Global Reach in Healthcare BioDlink's Bevacizumab Injection has received marketing authorization in Nigeria, boosting its global footprint. The approval addresses urgent healthcare needs in Africa.

BioDlink's Bevacizumab Gains Nigeria Approval, Enhancing Global Reach in Healthcare #None #Nigeria #BioDlink #Bevacizumab

Thiard News@F4F

@newsen.bsky.social

9 months ago

BioDlink Achieves Significant GMP Certification Milestone in Argentina for Global Expansion BioDlink Biopharm has obtained GMP certification from Argentina, enhancing its global presence and commitment to oncological therapies with Pusintin® injection.

BioDlink Achieves Significant GMP Certification Milestone in Argentina for Global Expansion #Suzhou #Argentina #Kexing_Biopharm #BioDlink #Pusintin

Thiard News@F4F

@newsen.bsky.social

9 months ago

BioDlink Secures GMP Certification in Brazil to Enhance Global Reach BioDlink's successful GMP audit in Brazil marks a significant milestone in its expansion into emerging markets, particularly in oncology treatments. This approval strengthens its commitment to quality.

BioDlink Secures GMP Certification in Brazil to Enhance Global Reach #China #Suzhou #Brazil #GMP #BioDlink

Thiard News@F4F

@newsen.bsky.social

10 months ago

BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy BioDlink proudly announces Junshi Biosciences' IND approval for JS212, a bispecific ADC aimed at treating various cancers. This milestone showcases advanced therapeutic advancements.

BioDlink Celebrates Junshi Biosciences' IND Approval for JS212 Therapy #China #Suzhou #BioDlink #Junshi_Biosciences #JS212